The impact of a pneumococcal vaccination on disease activity in children and adolescents with inflammatory bowel disease: a 2-year prospective study

Read full text Summarise with VIRAT
Authors: Magdalena Neścioruk, Kinga Kowalska‐Duplaga, Urszula Grzybowska‐Chlebowczyk, Agnieszka Sieczkowska, Aleksandra Banaszkiewicz
Cited by: 0

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Infectious diseases are known triggers for inflammatory bowel disease (IBD) exacerbations. Although vaccines can prevent many such infections, hesitancy persists among pediatric IBD patients and their caregivers due to concerns about vaccine-induced disease flare-ups. The aim of the study was to evaluate the impact of the 13-valent pneumococcal conjugate vaccine (PCV13) on disease activity in children and adolescents with IBD over a 24-month period post-vaccination. This prospective, multicenter cohort study included IBD patients aged 4–18 years. Participants were assigned to a vaccinated group (single PCV13 dose) or an unvaccinated control group. Disease activity was monitored using PUCAI/PCDAI scores, and exacerbation rates were recorded at 6, 12, 18, and 24 months. A total of 279 patients (52.3% male; median age, 167 months) were enrolled, of whom 93 (33.3%) received PCV13. The control group showed higher, but not statistically significant, disease activity at any time point (p = 0.06, 0.10, 0.64, 0.36) and exacerbation rates (p = 0.47, 0.17, 0.82, 0.75). A single dose of PCV13 does not increase disease activity in pediatric IBD patients during the 24 months following vaccination.

Fields of Study & Subjects

Inflammatory Bowel Disease Ocular Diseases and Behçet’s Syndrome Pharmacovigilance and Adverse Drug Reactions

Publication details

Journal / source
Figshare
Publication date
28 March 2026
Language
EN